




RealRate

HEALTH SERVICES 2023

Lisata Therapeutics INC Rank 37 of 101





RealRate

HEALTH SERVICES 2023

Lisata Therapeutics INC Rank 37 of 101



The relative strengths and weaknesses of Lisata Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lisata Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 154% points. The greatest weakness of Lisata Therapeutics INC is the variable Net Income, reducing the Economic Capital Ratio by 64% points.

The company's Economic Capital Ratio, given in the ranking table, is 175%, being 37% points above the market average of 138%.

Input Variable	Value in 1000 USD
Assets, Current	71,876
Assets, Non-Current	528
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	14,141
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	6,383
Long Term Liabilities	327
Operating Costs and Expenses	0
Other Assets	334
Other Compr. Net Income	41
Other Expenses	40,981
Other Liabilities	0
Other Net Income	897
Other Revenues	0
Property Plant and Equipment	296
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	73,034
Liabilities	6,710
Expenses	55,122
Revenues	0
Stockholders Equity	66,324
Net Income	-54,225
Comprehensive Net Income	-54,184
BaseVar	67,902
ECR before LimitedLiability	105%
Economic Capital Ratio	175%